AMGEN INC (AMGN) Fundamental Analysis & Valuation

NASDAQ:AMGN • US0311621009

Current stock price

340.275 USD
-2.3 (-0.67%)
Last:

This AMGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. AMGN Profitability Analysis

1.1 Basic Checks

  • AMGN had positive earnings in the past year.
  • AMGN had a positive operating cash flow in the past year.
  • AMGN had positive earnings in each of the past 5 years.
  • Each year in the past 5 years AMGN had a positive operating cash flow.
AMGN Yearly Net Income VS EBIT VS OCF VS FCFAMGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

1.2 Ratios

  • With an excellent Return On Assets value of 8.51%, AMGN belongs to the best of the industry, outperforming 92.84% of the companies in the same industry.
  • AMGN's Return On Equity of 89.06% is amongst the best of the industry. AMGN outperforms 99.23% of its industry peers.
  • With an excellent Return On Invested Capital value of 16.85%, AMGN belongs to the best of the industry, outperforming 96.71% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for AMGN is significantly below the industry average of 27.63%.
  • The 3 year average ROIC (14.35%) for AMGN is below the current ROIC(16.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.51%
ROE 89.06%
ROIC 16.85%
ROA(3y)6.63%
ROA(5y)7.92%
ROE(3y)88.81%
ROE(5y)106.67%
ROIC(3y)14.35%
ROIC(5y)15.45%
AMGN Yearly ROA, ROE, ROICAMGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50 100 150

1.3 Margins

  • With an excellent Profit Margin value of 20.98%, AMGN belongs to the best of the industry, outperforming 93.04% of the companies in the same industry.
  • AMGN's Profit Margin has declined in the last couple of years.
  • With an excellent Operating Margin value of 34.19%, AMGN belongs to the best of the industry, outperforming 96.33% of the companies in the same industry.
  • AMGN's Operating Margin has improved in the last couple of years.
  • The Gross Margin of AMGN (73.30%) is better than 81.62% of its industry peers.
  • AMGN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 34.19%
PM (TTM) 20.98%
GM 73.3%
OM growth 3Y4.6%
OM growth 5Y4.15%
PM growth 3Y-5.54%
PM growth 5Y-5.99%
GM growth 3Y2.93%
GM growth 5Y1.72%
AMGN Yearly Profit, Operating, Gross MarginsAMGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. AMGN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so AMGN is creating value.
  • AMGN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for AMGN has been reduced compared to 5 years ago.
  • AMGN has a better debt/assets ratio than last year.
AMGN Yearly Shares OutstandingAMGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
AMGN Yearly Total Debt VS Total AssetsAMGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • The Debt to FCF ratio of AMGN is 6.74, which is on the high side as it means it would take AMGN, 6.74 years of fcf income to pay off all of its debts.
  • AMGN's Debt to FCF ratio of 6.74 is amongst the best of the industry. AMGN outperforms 90.72% of its industry peers.
  • AMGN has a Debt/Equity ratio of 5.78. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of AMGN (5.78) is worse than 82.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.78
Debt/FCF 6.74
Altman-Z N/A
ROIC/WACC1.86
WACC9.07%
AMGN Yearly LT Debt VS Equity VS FCFAMGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 1.14 indicates that AMGN should not have too much problems paying its short term obligations.
  • AMGN has a worse Current ratio (1.14) than 84.72% of its industry peers.
  • A Quick Ratio of 0.90 indicates that AMGN may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.90, AMGN is not doing good in the industry: 86.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.9
AMGN Yearly Current Assets VS Current LiabilitesAMGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMGN Growth Analysis

3.1 Past

  • AMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.24%, which is quite good.
  • Measured over the past 5 years, AMGN shows a small growth in Earnings Per Share. The EPS has been growing by 5.65% on average per year.
  • Looking at the last year, AMGN shows a quite strong growth in Revenue. The Revenue has grown by 9.95% in the last year.
  • Measured over the past years, AMGN shows a small growth in Revenue. The Revenue has been growing by 7.65% on average per year.
EPS 1Y (TTM)10.24%
EPS 3Y7.29%
EPS 5Y5.65%
EPS Q2Q%-0.38%
Revenue 1Y (TTM)9.95%
Revenue growth 3Y11.77%
Revenue growth 5Y7.65%
Sales Q2Q%8.58%

3.2 Future

  • Based on estimates for the next years, AMGN will show a small growth in Earnings Per Share. The EPS will grow by 4.89% on average per year.
  • The Revenue is expected to grow by 3.17% on average over the next years.
EPS Next Y4.46%
EPS Next 2Y4.2%
EPS Next 3Y4.06%
EPS Next 5Y4.89%
Revenue Next Year4.1%
Revenue Next 2Y3.29%
Revenue Next 3Y3.03%
Revenue Next 5Y3.17%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMGN Yearly Revenue VS EstimatesAMGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
AMGN Yearly EPS VS EstimatesAMGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

6

4. AMGN Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.57 indicates a correct valuation of AMGN.
  • 94.97% of the companies in the same industry are more expensive than AMGN, based on the Price/Earnings ratio.
  • AMGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.21.
  • AMGN is valuated correctly with a Price/Forward Earnings ratio of 14.91.
  • 95.74% of the companies in the same industry are more expensive than AMGN, based on the Price/Forward Earnings ratio.
  • AMGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.13.
Industry RankSector Rank
PE 15.57
Fwd PE 14.91
AMGN Price Earnings VS Forward Price EarningsAMGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 94.78% of the companies in the same industry are more expensive than AMGN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 22.65
EV/EBITDA N/A
AMGN Per share dataAMGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • AMGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.49
PEG (5Y)2.76
EPS Next 2Y4.2%
EPS Next 3Y4.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. AMGN Dividend Analysis

5.1 Amount

  • AMGN has a Yearly Dividend Yield of 2.89%. Purely for dividend investing, there may be better candidates out there.
  • AMGN's Dividend Yield is rather good when compared to the industry average which is at 1.11. AMGN pays more dividend than 98.84% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, AMGN pays a better dividend.
Industry RankSector Rank
Dividend Yield 2.89%

5.2 History

  • On average, the dividend of AMGN grows each year by 9.41%, which is quite nice.
  • AMGN has been paying a dividend for at least 10 years, so it has a reliable track record.
  • AMGN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)9.41%
Div Incr Years14
Div Non Decr Years14
AMGN Yearly Dividends per shareAMGN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6 8

5.3 Sustainability

  • The dividend of AMGN is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP0%
EPS Next 2Y4.2%
EPS Next 3Y4.06%
AMGN Yearly Income VS Free CF VS DividendAMGN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

More info and screens

Find the best dividend stocksShow peers with best dividend

AMGN Fundamentals: All Metrics, Ratios and Statistics

AMGEN INC

NASDAQ:AMGN (4/7/2026, 2:00:09 PM)

340.275

-2.3 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-03
Earnings (Next)04-29
Inst Owners85.05%
Inst Owner Change0%
Ins Owners0.06%
Ins Owner Change3.94%
Market Cap183.43B
Revenue(TTM)36.75B
Net Income(TTM)7.71B
Analysts70.7
Price Target360.65 (5.99%)
Short Float %2.66%
Short Ratio4.96
Dividend
Industry RankSector Rank
Dividend Yield 2.89%
Yearly Dividend9.01
Dividend Growth(5Y)9.41%
DP0%
Div Incr Years14
Div Non Decr Years14
Ex-Date05-15
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.92%
Min EPS beat(2)9.56%
Max EPS beat(2)10.28%
EPS beat(4)4
Avg EPS beat(4)10.8%
Min EPS beat(4)9.56%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)6.29%
EPS beat(12)11
Avg EPS beat(12)5.41%
EPS beat(16)14
Avg EPS beat(16)4.51%
Revenue beat(2)2
Avg Revenue beat(2)3.3%
Min Revenue beat(2)2.11%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)4
Avg Revenue beat(8)0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.22%
Revenue beat(16)6
Avg Revenue beat(16)-0.27%
PT rev (1m)0.11%
PT rev (3m)7.76%
EPS NQ rev (1m)-1.38%
EPS NQ rev (3m)-6.12%
EPS NY rev (1m)0%
EPS NY rev (3m)1.9%
Revenue NQ rev (1m)-0.53%
Revenue NQ rev (3m)-0.65%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)2.32%
Valuation
Industry RankSector Rank
PE 15.57
Fwd PE 14.91
P/S 4.99
P/FCF 22.65
P/OCF 18.42
P/B 21.19
P/tB N/A
EV/EBITDA N/A
EPS(TTM)21.85
EY6.42%
EPS(NY)22.82
Fwd EY6.71%
FCF(TTM)15.03
FCFY4.42%
OCF(TTM)18.47
OCFY5.43%
SpS68.17
BVpS16.06
TBVpS-59.91
PEG (NY)3.49
PEG (5Y)2.76
Graham Number88.86
Profitability
Industry RankSector Rank
ROA 8.51%
ROE 89.06%
ROCE 19.3%
ROIC 16.85%
ROICexc 19.6%
ROICexgc 73.08%
OM 34.19%
PM (TTM) 20.98%
GM 73.3%
FCFM 22.04%
ROA(3y)6.63%
ROA(5y)7.92%
ROE(3y)88.81%
ROE(5y)106.67%
ROIC(3y)14.35%
ROIC(5y)15.45%
ROICexc(3y)16.88%
ROICexc(5y)18.44%
ROICexgc(3y)72.7%
ROICexgc(5y)79.08%
ROCE(3y)16.43%
ROCE(5y)17.69%
ROICexgc growth 3Y-3.21%
ROICexgc growth 5Y2.03%
ROICexc growth 3Y4.63%
ROICexc growth 5Y5.17%
OM growth 3Y4.6%
OM growth 5Y4.15%
PM growth 3Y-5.54%
PM growth 5Y-5.99%
GM growth 3Y2.93%
GM growth 5Y1.72%
F-Score7
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 5.78
Debt/FCF 6.74
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 5.06%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 105.05%
Current Ratio 1.14
Quick Ratio 0.9
Altman-Z N/A
F-Score7
WACC9.07%
ROIC/WACC1.86
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.09%
Cap/Sales(5y)3.84%
Profit Quality(3y)156.25%
Profit Quality(5y)149.01%
High Growth Momentum
Growth
EPS 1Y (TTM)10.24%
EPS 3Y7.29%
EPS 5Y5.65%
EPS Q2Q%-0.38%
EPS Next Y4.46%
EPS Next 2Y4.2%
EPS Next 3Y4.06%
EPS Next 5Y4.89%
Revenue 1Y (TTM)9.95%
Revenue growth 3Y11.77%
Revenue growth 5Y7.65%
Sales Q2Q%8.58%
Revenue Next Year4.1%
Revenue Next 2Y3.29%
Revenue Next 3Y3.03%
Revenue Next 5Y3.17%
EBIT growth 1Y73.11%
EBIT growth 3Y16.9%
EBIT growth 5Y12.12%
EBIT Next Year31.85%
EBIT Next 3Y9.8%
EBIT Next 5Y8.55%
FCF growth 1Y-22.07%
FCF growth 3Y-2.67%
FCF growth 5Y-3.91%
OCF growth 1Y-13.33%
OCF growth 3Y0.81%
OCF growth 5Y-1.05%

AMGEN INC / AMGN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AMGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to AMGN.


What is the valuation status of AMGEN INC (AMGN) stock?

ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.


How profitable is AMGEN INC (AMGN) stock?

AMGEN INC (AMGN) has a profitability rating of 8 / 10.


What are the PE and PB ratios of AMGEN INC (AMGN) stock?

The Price/Earnings (PE) ratio for AMGEN INC (AMGN) is 15.57 and the Price/Book (PB) ratio is 21.19.


How financially healthy is AMGEN INC?

The financial health rating of AMGEN INC (AMGN) is 3 / 10.